Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | IAPP | P10997 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899013 | 1.00 | MAPT (0.66) | MAPTLMNAKDM4EIAPPGLA | |
| SCHEMBL2834883 | 1.00 | MAPT (0.66) | MAPTLMNAKDM4EIAPPGLA | |
| SCHEMBL31422587 | 1.00 | MAPT (0.66) | MAPTLMNAKDM4EIAPPGLA | |
| SCHEMBL14441077 | 0.87 | MAPT (0.76) | MAPTLMNAKDM4EIAPPGLA | |
| SCHEMBL15853343 | 0.86 | LMNA (0.50) | MAPTLMNAKDM4EIAPPGLA | |
| SCHEMBL5598952 | 0.85 | NFE2L2 (0.61) | MAPTLMNAKDM4ETDP1ALDH1A1 | |
| SCHEMBL5598954 | 0.85 | NFE2L2 (0.61) | MAPTLMNAKDM4ETDP1ALDH1A1 | |
| SCHEMBL78556 | 0.83 | CA1 (0.62) | MAPTLMNAKDM4EALDH1A1TSHR | |
| SCHEMBL78555 | 0.83 | CA1 (0.62) | MAPTLMNAKDM4EALDH1A1TSHR | |
| SCHEMBL2425317 | 0.83 | CA1 (0.62) | MAPTLMNAKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795600-B2 | Method for treating abnormal β-amyloid mediated diseases | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2017-10-24 | — | — | US | disclosed |
| US-20160143899-A1 | METHOD FOR TREATING ABNORMAL B-AMYLOID MEDIATED DISEASES | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2016-05-26 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-7335419-B2 | System and method for energy-conserving roofing | AZARI SHAUN | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143899-A1 | METHOD FOR TREATING ABNORMAL B-AMYLOID MEDIATED DISEASES | APOB, APP, TTR | MAPT 11/4885LMNA 351/4885KDM4E 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.